CliffBio
small molecule

TEKTURNA

ALISKIREN HEMIFUMARATE

Loss of exclusivity—loss of exclusivity
CompanyNODEN PHARMA DAC

Drug detail

Brand nameTEKTURNA
Active ingredientALISKIREN HEMIFUMARATE
StrengthEQ 37.5MG BASE
Dosage formCAPSULE, PELLET
RouteORAL
ModalitySmall molecule
FDA approvalNovember 2017
Marketing statusDISCN

More from NODEN PHARMA DAC

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.

TEKTURNA patent cliff — loss of exclusivity — | CliffBio